NERLYNX for HER2+ breast cancer

I'm doing everything in my power
so I can keep
doing what I love.

For early-stage breast cancer* Updated early-stage breast cancer data* For metastatic breast cancer Updated early-stage breast cancer data*

Not an actual patient.

*Patients who have previously been treated with trastuzumab-based therapy.

Patients who have received 2 or more anti-HER2 therapies used in combination with capecitabine.

Updated Dosing Information 

Updated dosing information.

See Patient Information or talk to your healthcare provider to learn more.

Mentor Program

Connect with real women and learn more about what to expect

Connect now
Nurse Support

Our team of registered nurses can answer your questions throughout treatment

Learn more
FAQs

Get to know NERLYNX by viewing answers to common questions

View now

Our support services are designed for you

Currently taking or thinking about taking NERLYNX? There's ongoing support built just for you. Sign up here to receive information and updates specific to your HER2+ breast cancer.

What is your HER2+ breast cancer diagnosis?

Have you been prescribed NERLYNX?

All information collected will be used for sending updates only and will not be shared with third parties. By providing your email you are agreeing to receive communications. For more details, see our privacy policy.

Connect with us

Select IMPORTANT SAFETY INFORMATION

The most common side effects of NERLYNX when used alone include:

  • diarrhea
  • nausea
  • stomach-area (abdomen) pain
  • tiredness
  • vomiting
  • rash
  • dry or inflamed mouth, or mouth sores
  • decreased appetite
  • muscle spasms
  • upset stomach
  • nail problems including color change
  • dry skin
  • swelling of your stomach-area
  • nosebleed
  • weight loss
  • urinary tract infection

The most common side effects of NERLYNX when used with capecitabine include:

  • diarrhea
  • nausea
  • vomiting
  • decreased appetite
  • constipation
  • tiredness/weakness
  • weight loss
  • dizziness
  • back pain
  • joint pain
  • urinary tract infection
  • upper respiratory tract infection
  • swelling of your stomach-area
  • kidney problems
  • muscle spasms

These are not all of the possible side effects of NERLYNX. For more information, ask your Healthcare Provider.

Please see additional IMPORTANT SAFETY INFORMATION below.

What is NERLYNX tablets?

It is not known if NERLYNX is safe and effective in children.


IMPORTANT SAFETY INFORMATION

What is the most important information I should know about NERLYNX (ner links)?

NERLYNX may cause serious side effects, including:

Your healthcare provider may change your dose of NERLYNX, temporarily stop, or completely stop NERLYNX if needed to manage your diarrhea.

See "What are the possible side effects of NERLYNX?" for more information about side effects.

Before taking NERLYNX, tell your healthcare provider about all of your medical conditions, including if you:

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.

Especially tell your healthcare provider if you take medicines used to decrease stomach acid, called proton pump inhibitors or PPIs. You should avoid taking these medicines during treatment with NERLYNX.

What should I avoid while taking NERLYNX?
You should avoid eating products that contain grapefruit during treatment with NERLYNX.

What are the possible side effects of NERLYNX?

NERLYNX may cause serious side effects, including:
See "What is the most important information I should know about NERLYNX?"


The most common side effects of NERLYNX when used alone include:

The most common side effects of NERLYNX when used with capecitabine include:

These are not all of the possible side effects of NERLYNX. For more information, ask your Healthcare Provider.

Tell your healthcare provider if you have any side effects that bother you or that does not go away. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

Please see Patient Information.